drugset / Trial / NCT07049068

Comparison of Nicotinamide Treatments for Actinic Keratosis

NCT07049068

RandomizedParallel-groupTriple-blindTreatment

Summary

In this study, the investigators aimed to evaluate the effect of oral nicotinamide compared to topical nicotinamide in the presence of actinic keratoses on the face. The reason that led the investigators to study this subject is that previous studies have shown possible favorable effects of nicotinamide, both topical and oral, in the prevention of precursor lesions of skin cancer. However, there are no studies to date comparing topical and oral presentations of nicotinamide in the prevention of the appearance of actinic keratoses and in the regression of the number of actinic keratoses. In this randomized clinical trial, 74 participants with actinic keratoses on the face received either oral nicotinamide and topical placebo or topical nicotinamide and oral placebo for 6 months.

Timeline

Start
2022-02-01
Primary completion
2024-11-30
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicotinamide Other / unclassified 5 % Oral
Comparator Nicotinamide Other / unclassified 500 mg Oral

Indications